FDA Adverse Event Injury Summary report: N

HUMAPEN ERGO, UNK PEN BODY TYPE/UNK CH TYPE

MDR report key: 1150556 · Received September 4, 2008

Report

Report Number
1819470-2008-00045
Event Type
Injury
Date Received
September 4, 2008
Report Date
August 11, 2008
Manufacturer
ELI LILLY AND CO.
Product Code
FMF
PMA / PMN Number
K982842
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
CA
Reporter Occupation
NOT APPLICABLE

Narratives

Additional Manufacturer Narrative · 1

IF DEVICE IS RETURNED, EVAL WILL BE PERFORMED TO DETERMINE IF A MALFUNCTION HAS OCCURRED. NOTE: THIS IS AN INITIAL REPORT. A FOLLOW-UP REPORT WILL BE SUBMITTED WHEN THE FINAL EVAL IS COMPLETED.

Description of Event or Problem · 1

THIS CASE REPORTED BY A CONSUMER, WHO CONTACTED THE COMPANY FOR PRODUCT INFO, CONCERNED A FEMALE PT OF UNK AGE AND ORIGIN. MEDICAL HISTORY INCLUDED BEING DIABETIC FOR 50 YEARS (1960) AND HISTORICAL USE OF ANIMAL INSULIN 25 YEARS AGO (1983). CONCOMITANT MEDICAL INCLUDED INSULIN GLARGINE. THE PT RECEIVED INSULIN LISPRO (HUMALOG) VIA CARTRIDGE PER A HUMAPEN (HP) ERGO: UNK BODY TYPE, DOSING REGIMEN UNSPECIFIED, FOR THE TREATMENT OF DIABETES, BEGINNING ON AN UNSPECIFIED DATE. THE PT EXPERIENCED HER BLOOD SUGARS BECAME IRREGULAR AND FAINTED (DATE UNSPECIFIED) TO WHERE THE PARAMEDICS WERE CALLED AND WAS PUT ON INTRAVENOUS (IV) GLUCOSE. THE PT ALSO REPORTED THAT SHE WENT HYPOGLYCEMIC MOSTLY WHEN REACHING THE END OF THE CARTRIDGES. IT WAS UNK IF SHE RECOVERED FROM ANY OF THE EVENTS. THE MEDICATION ACTION TAKEN WITH HUMALOG WAS NOT PROVIDED. THIS HP ERGO REPORT INCLUDED A PRODUCT COMPLAINT, SUSPECT DEVICE (ATTEMPTED TO OBTAIN LOT NUMBER; INFO UNK). IT WAS UNK IF THE PT WAS A TRAINED USER OF THE DEVICE. GENERAL DEVICE AND PROBLEM DEVICE DURATION OF US WAS NOT PROVIDED. THE PEN WITH THE PROBLEM WAS USED AND ITS RETURN STATUS WAS NOT PROVIDED. ADDITIONAL INFO WILL BE REQUESTED.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
1 HUMAPEN ERGO, UNK PEN BODY TYPE/UNK CH TYPE PEN INJECTOR FOR TREATMENT PURPOSES FMF ELI LILLY AND CO. UNK UNK

Patients

Seq Age Sex Outcome Treatment
1 UNK Required Intervention